Ticker

Chiron Real Estate is rated a 'buy' due to a significant margin of safety versus intrinsic value and a compelling 8.5% monthly dividend yield. XRN's portfolio is diversified across healthcare assets, with manageable tenant and geographic concentration; no major refinancing risk exists until after 2027. At $35.24, XRN trades at ~9x FFO, well below its historical multiple and 32% below intrinsic value, offering a…

BETHESDA, Md.--(BUSINESS WIRE)--Chiron Real Estate Inc. (NYSE: XRN) (the “Company”), announced today that it intends to release its first quarter 2026 financial results after the market closes on Wednesday, May 6, 2026. The Company intends to hold a conference call to discuss those results the following day, Thursday, May 7, 2026, at 9:00 a.m. Eastern Time. The conference call will be hosted by President and Chief…

Monthly pay dividend equities offer high yields and potential gains, with the top ten broker-estimated MoPay stocks projected to net 27.10%–65.84% by 2027. BCP Investment Corp (BCIC), CION Investment Corp (CION), and Dynex Capital (DX) stand out for both yield and upside, with CION forecasted to deliver a 45.69% net gain. Thirty 'IDEAL' MoPay equities are highlighted for safer dividends, combining positive one-year…

High-yield 'mousetrap' REITs consistently underperform, with significant risk of dividend cuts and capital loss, as evidenced by recent 12-month returns lagging VNQ by over 1,000 bps. Dividend Safety scores are critical; REITs rated F face a 40% chance of a cut within 12 months, often resulting in sharp share price declines. Key danger signals include high payout ratios, weak revenues, and heavy debt loads.

JPMorgan Chase and Co. reduced its position in shares of Global Medical REIT Inc. (NYSE: XRN) by 72.8% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 109,144 shares of the company's stock after selling 291,977 shares during the quarter. JPMorgan Chase and